Insights

As we continue to evolve our brand to Cencora, you will continue to see visual changes. We will be sunsetting amerisourcebergen.com over time and are actively moving content and information over to cencora.com. Please visit cencora.com if you can't find what you are looking for here.

Visit Cencora

Insights

Perspective, tips, and resources for moving health forward

All Insights Health Systems Pharmacies Physician Practices Manufacturers Animal Health

AmerisourceBergen

Cencora PayerPulse: The unintended consequences of the Inflation Reduction Act (IRA)

AmerisourceBergen

September 2024

Manufacturers

Panel discussion: Strategically prepare for IRA Part D redesign

AmerisourceBergen

Webinar

Manufacturers

HTA Quarterly Fall 2024

AmerisourceBergen

In this special themed edition, our colleagues at Vintura, a Cencora company, explore the potential of value-based partnerships (VBPs). First outlining the principles, goals and potential benefits of VBPs, this edition also provides two case studies that demonstrate how successful partnerships work in practice.

Embracing value-based partnerships: A path to enhanced healthcare outcomes

Rianne Ernst, MSc; Carlijn de Sonnaville, MSc; Silvia Rohr, PhD; Mark Tolboom, MSc

Vintura, a Cencora company

htaq

Manufacturers

EU HTA 2025 readiness: Key methodological updates and practical tips on statistical guidelines

Michael Hennig, PhD

PharmaLex, part of Cencora

Market research images on ipad

From PICO anxiety to PICO strategy: planning for EU HTA success

Ruairi O'Donnell, PhD

Does EU HTAR put patients at the center

Manufacturers

Get set for 2025: Mastering the new EU HTA statistical guidelines

AmerisourceBergen

EU HTA Statistical Guidelines

Manufacturers

Value-Based Healthcare (VBHC): A game changer for pharma to accelerate patient access

AmerisourceBergen

Market access

Manufacturers

4 questions with Joanna Ng

Manufacturers

Unsupported policy information: Insights from Jane Ha

Jane Ha, PharmD, MS

Manufacturers

Decoding payer perspectives: Insights from Ben Penley

Manufacturers

Leveraging Pre-Approval Information Exchange to Accelerate Product Success and Patient Access

Legislation

Manufacturers

Forging ahead with US and EU healthcare policy changes: balancing sustainability, innovation and patient access in the era of IRA and EU HTA

AmerisourceBergen

Manufacturers

Emerging biopharma Outlook Therapeutics shares the benefits of Cencora's international commercialization support

AmerisourceBergen

Manufacturers

Value-Based Healthcare (VBHC): A game changer for pharma to accelerate patient access

AmerisourceBergen

webinar_RGB_Large_JPG

Manufacturers

Q&A on the latest guidelines for statistical analysis in EU Health Technology Assessment

Michael Hennig, PhD

PharmaLex, part of Cencora

lash group consultation

Manufacturers

4 questions with Ben Penley

AB-Business-Meeting-Two-Males_RGB_Large-Square

Manufacturers

5 questions with Jane Ha

Jane Ha, PharmD, MS

meeting

Manufacturers

6 questions with Kyle Noonan

Kyle Noonan, PharmD, MS

meeting

Manufacturers

Recap AMCP 2024: Our thought leadership in action

AmerisourceBergen

amcp

Q&A Interview: Navigating the launch of ATMPs in Europe

AmerisourceBergen

regulatory services_top banner

Manufacturers

Benefit-driven pricing: How AMNOG strikes a balance between the financial burden on statutory health insurance and reimbursement of innovative medications in Germany

Annika Brosig, PhD; Kristina Dittrich, PhD; Werner Kulp, PhD; Jan-Frederik Löpmeier-Röh, MSc; Edith Wehage, PhD

AMNOG strikes a balance

Manufacturers

Embarking on the EU HTAR realization journey: Key insights from the first of six implementing acts

Mareike Konstanski, MSc; Susanne Kossow, PhD; Ruairi O'Donnell, PhD; Kim Joline Schmidt, MSc

HTA JCA implementing acts

Manufacturers

EAMS evidence: A key player in drug value proposition and NICE approval?

David Ringger; Erika Wissinger, PhD

EAMS

Manufacturers

HTAQ Summer 2024

AmerisourceBergen

In this edition, we continue the series on preparations for European Union (EU) HTA now the draft implementing act on procedural rules for Joint Clinical Assessment (JCA) of medicinal products has been published. Additionally, two country-specific analyses consider the impact of AMNOG benefit assessment on drug pricing in Germany, and the impact of participation in the UK’s Early Access to Medicines Scheme (EAMS) on recommendations from the National Institute for Health and Care Excellence (NICE).

Manufacturers

Market access brochure

AmerisourceBergen

Cell and gene therapy commercialization

Manufacturers

Anticipating issues, tackling challenges: Next steps with the JCA

AmerisourceBergen

jca

Manufacturers

Are alternative access pathways the key to success for small pharma in European markets?

AmerisourceBergen

Map of Europe

Manufacturers

Government Reliance on Value Assessments in Medicare Part B

AmerisourceBergen

abstract lines

Manufacturers

Webinar Insights: Navigating the changing landscape of Inflation Reduction Act (IRA) negotiations

AmerisourceBergen

US Capitol building

Manufacturers

Navigating new access hurdles in Europe: A conversation with Cencora’s EU HTA Lead

Ruairi O'Donnell, PhD

professionals around computer monitor

Manufacturers

Is NICE’s disease severity classification at risk?

AmerisourceBergen

consulting

Manufacturers

HTA Quarterly Spring 2024

AmerisourceBergen

Manufacturers

Rating the robots: Artificial intelligence for literature reviews

Malia Gill, MS; Kimberly Ruiz, EdM; Fi Stewart, MSc; Erika Wissinger, PhD

Rating AI for Lit reviews

Manufacturers

It’s Just…So…Cool – Don’t miss your opportunity for JSC!

Kim Joline Schmidt, MSc; Mareike Konstanski, MSc; Erika Wissinger, PhD; Patrick Blank, PhD

Awaiting the JCA implementing acts

Manufacturers

Apples to apples, or apples to oranges? Comparing the Inflation Reduction Act to drug-pricing programs in other countries

Scott Shields, MBA

Advanced therapies week

Manufacturers

Executive Insights: What's next with the Inflation Reduction Act (IRA)

AmerisourceBergen

US Capitol building

Manufacturers

Planning for the World: Q&A With Sandra Anderson, SVP of International Commercialization at Cencora

AmerisourceBergen

Manufacturers

Addressing Barriers to Patient Care for People Living With Atopic Dermatitis

Leigh Gallo; Victoria Loo, MPH; Scott Shields, MBA

patient care

Shaping the future of healthcare: Our thought leadership at ISPOR Europe 2023

AmerisourceBergen

iStock-491119888

Manufacturers

Anticipating the top seven global market access trends for 2024: Cencora’s healthcare landscape outlook

AmerisourceBergen

global market access trends in 2024

Manufacturers

Podcast: How 2023 will shape the US Biosimilar space for 2024 and beyond

AmerisourceBergen

Vials

Manufacturers

The Dutch Lock Procedure for Reimbursement: Ensuring Effective and Affordable Healthcare

AmerisourceBergen

Hands and blocks building strategy

Manufacturers

Enhancing Patient-Reported Outcomes (PROs) in German AMNOG Assessments: Insights from the ISPOR Europe 2023 Conference

AmerisourceBergen

globe with stethoscope

Manufacturers

Will the IRA hinder the potential of Biosimilars?

AmerisourceBergen

Biosimilars gears htaq

Manufacturers

Patients at the center – Does the JCA truly embrace the patients’ voice?

AmerisourceBergen

EU JCA Patients at the center

Manufacturers

Exploring the Implications of Differing PICO Criteria for Oncology Drug Assessments in Europe

AmerisourceBergen

jca

Manufacturers

Unlocking the Potential of Joint Clinical Assessment (JCA) in Europe: Insights from Industry Leaders and Experts

AmerisourceBergen

bright tubes

Manufacturers

Webinar on demand: Implications of the EU JCA on patient access and engagement

AmerisourceBergen

PageDesign_Patient_Doc

Manufacturers

Cost and resource burden of coverage with evidence development

Victoria Loo, MPH; Scott Shields, MBA

Cost and Resource Burden

Manufacturers

Does the EU HTAR really put patients at the center?

AmerisourceBergen

Does EU HTAR put patients at the center

Manufacturers

HTA Quarterly Winter 2023

AmerisourceBergen

HTA Quarterly

Manufacturers

Navigating the way to the new EU JCA—Are biopharma companies, HTA bodies, patients, and clinicians sufficiently prepared?

Kim Joline Schmidt, MSc; Mareike Konstanski, MSc; Ruairi O'Donnell, PhD; Erika Wissinger, PhD; Herbert Altmann, PhD

EU JCA countdown

Manufacturers

Gauge the impact: What does the striking down of a federal copay accumulator regulation mean for patients and copay programs?

AmerisourceBergen

US capitol color

Manufacturers

Valuing potential cures: An examination of ICER’s approach to assessing high-impact single and short-term therapies

AmerisourceBergen

GettyImages-1139001612_RGB_Large_JPG (1)

Manufacturers

First 10 drugs for Medicare price negotiation announced under IRA

Corey Ford, MHA

Washington DC Capital

Manufacturers

Q&A – Preparing for the EU Joint Clinical Assessment (JCA) process

AmerisourceBergen

The EU JCA process

HTA Quarterly | Fall 2023

Manufacturers

Only 17 months until the implementation of the new EU JCA—Latest developments and remaining uncertainties

AmerisourceBergen

implementation of the new EU JCA

Manufacturers

The cures conundrum: The importance of getting value assessment right for transformational therapies

AmerisourceBergen

getting value assessment right for transformational therapies

Manufacturers

VPAS—Where next?

AmerisourceBergen

VPAS What's Next

Manufacturers

Podcast: Collaborative perseverance to bring change to medicine access

AmerisourceBergen

insights into the workings of the JCA process

Manufacturers

Multistakeholder perspectives on Joint Clinical Assessment in Europe

AmerisourceBergen

Group Physicians Wearing Masks

Panel explores insights and implications of the game-changing EU JCA

AmerisourceBergen

jca eu hta

Manufacturers

Pharma Europe Q&A

AmerisourceBergen

Pharma Europe QA

Manufacturers

Empower your people and brand with biopharma learning solutions

AmerisourceBergen

Middle-aged woman in wheelchair draws on a white board

Manufacturers

On-demand webinar: The EU JCA process: Opportunities and challenges in bringing innovative medicines to patients in Europe

AmerisourceBergen

Reimbursement considerations for home infusions

Abstract

Manufacturers

How the JCA may help to address medicine inequality across Europe

AmerisourceBergen

eu flag

Manufacturers

Recap Asembia 2023: Our impactful contributions to the premier specialty pharmacy conference

AmerisourceBergen

Amerisourcebergen representatives at Asembia

Manufacturers

Recap AMCP 2023: Our thought leadership in action

Team members at the AMCP 2023 exhibit

Manufacturers

Answering four key questions about HTA market archetypes

AmerisourceBergen

Phacilitate Miami Advanced Therapies Week

Manufacturers

Six essential steps for emerging biopharma companies launching a new therapy

AmerisourceBergen

emerging biopharma companies launching their first therapy

Manufacturers

New pan-EU HTA: How can biopharma navigate the joint clinical assessment?

AmerisourceBergen

New Pan-EU HTA

Manufacturers

Innovation spotlight: Adding nursing support to at-home clinical trials

AmerisourceBergen

nurse and patient in home